VFM
HELP

Vision Financial Markets’s Helus Pharma Inc. Common Stock HELP Stock Holding History

Vision Financial Markets’s Portfolio HELP Stock Details HELP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2
Closed -$13 – 441
2025
Q1 		$13 Buy
+2
New +$17 ﹤0.01% 431

Other funds holding HELP

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $566M AUM 197.74% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
BG
Bollard Group Boston, Massachusetts $3.29B AUM 4.86% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Vision Financial Markets's HELP Position: Q2 2025 in Review

Vision Financial Markets sold out of Helus Pharma Inc. Common Stock (HELP) in Q2 2025, closing a stake of 2 shares — an estimated $13 sold.

Vision Financial Markets first reported a position in HELP in Q1 2025 and held it in 1 quarter. The position peaked at $13 in Q1 2025. 56 funds tracked by Wall St. Rank hold HELP as of Q2 2025.

  • Vision Financial Markets reported no remaining Helus Pharma Inc. Common Stock position as of Q2 2025 after selling out during the quarter.
  • Vision Financial Markets sold 2 Helus Pharma Inc. Common Stock shares in Q2 2025, an estimated $13.
  • Vision Financial Markets first reported a position in Helus Pharma Inc. Common Stock in Q1 2025 and held it in 1 quarter.
  • Vision Financial Markets's Helus Pharma Inc. Common Stock position peaked at $13 in Q1 2025.
  • 56 funds tracked by Wall St. Rank held Helus Pharma Inc. Common Stock as of Q2 2025.

Based on Vision Financial Markets's 13F filing for Q2 2025, filed 1 Aug 2025.